All In Biotech

Drug Trial Radar · NCT05078866

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome

Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

45

Actual

Start

Nov 10, 2022

Primary completion

Apr 16, 2025

Study completion Sep 30, 2026

Sponsor

Sponsor type
NIH
First posted
Oct 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase Ib/II trial evaluates the safety and effect of the Nous-209 vaccine in Lynch syndrome patients. Lynch syndrome is an inherited disorder in which affected individuals have a higher-than-normal chance of developing colorectal cancer and certain other types of cancer, often before the age of 50. In Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Neoantigens are recognized by the body's immune system as foreign, and the body tries to get rid of them. Nous-209 is a vaccine made with man-made copies of some of those neoantigens. This trial aims to see whether the Nous-209 vaccine is safe to give to patients with Lynch syndrome, whether people are able to take the Nous-209 vaccine without becoming too uncomfortable, and how the immune system of patients with Lynch syndrome respond to the Nous-209 vaccine. This trial may help researchers determine whether receiving Nous-209 have an effect on the development of polyps or tumors in the colon.

Conditions

  • Colorectal Carcinoma
  • Lynch Syndrome

Interventions

  • Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPBiological

    Given IM

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Endoscopic BiopsyProcedure

    Undergo endoscopy with biopsy

  • MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSPBiological

    Given IM

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rates of grade 2/3 adverse events and symptom reactivity following vaccinationTime frame: Up to 12 months
  2. Rate of immunogenicity following vaccination (Cohort I)Time frame: Baseline and week 9
  3. Rate of immunogenicity following revaccination (Cohort II)Time frame: Weeks 52 and at 8 weeks after the last boost with MVA-209-FSP (corresponding to week 68 and week 60, for arm A and B, respectively)
  4. Rates of grade 2/3 adverse events and symptom reactivity following revaccination (Cohort II)Time frame: Up to 12 months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • M D Anderson Cancer Center

    Houston, Texas

  • University of Puerto Rico

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.